Compare Repligen Corporation Common Stock (RGEN) vs TeraWulf Inc (WULF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs TeraWulf Inc — how do they compare? Repligen Corporation Common Stock trades at $178.19 (market cap $11.14B), while TeraWulf Inc trades at $11.31 (market cap $6.59B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, TeraWulf Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and TeraWulf Inc for 18 Days on average.
| RGEN | WULF | |
|---|---|---|
Market Cap | $11.14B | $6.59B |
Volume | 1,259,263 | 33,904,053 |
Sector | Health | Financials |
52-Week High | $194.57 | $28.98 |
52-Week Low | $102.87 | $10.99 |
Typical Hold Time | 0 Days | 18 Days |
Enterprise Value | $11.02B | $9.21B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
WULF trades at $13.21, down 1.2% on the day, with a bearish technical signal from moving averages. The company reported a net loss of -$661.42M in 2025, with a negative net income margin of -1,179.94%, though it maintains a high gross profit margin of 69.26%. Recent news highlights its pivot to AI data centers, with shares experiencing volatility amid sector-wide momentum.
Analyst consensus is strongly bullish with a $34.92 price target, but high valuation ratios and persistent losses pose significant risks. Investment appeal hinges on successful execution of the AI infrastructure strategy amid substantial financial leverage and competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About TeraWulf Inc
TeraWulf develops, owns, and operates fully integrated digital infrastructure powered by predominantly zero-carbon energy. It utilizes a hybrid business model that combines industrial-scale Bitcoin mining with high-performance computing (HPC) and AI hosting, leveraging sustainable power sources like nuclear and hydroelectric to deliver low-cost, energy-efficient data center solutions.
Read more on WULF →
